Related Experiment Video
Updated: Aug 22, 2026
Controlled Cortical Impact Model for Traumatic Brain Injury
Published on: August 5, 2014
Clinical trials in traumatic brain injury: current problems and future solutions
A I R Maas1, A Marmarou, G D Murray
1Department of Neurosurgery, Erasmus University Medical Center Rotterdam, Rotterdam, The Netherlands. airmaas@erasmusmc.nl
Abstract:
Over the past decade many neuroprotective agents have been developed with the hope of being able to improve outcome in patients with traumatic brain injury. Unfortunately, none of the phase III trials performed have convincingly demonstrated efficacy in the overall population. A common misconception is that consequently these agents are ineffective. Such has not been proven and some trials show evidence of efficacy in subgroups of the population studied. The negative results, as reported in the overall population, may in part be caused by specific aspects of the TBI population, as well as by aspects of clinical trial design and analysis. Clinical trials in TBI pose several complicated design issues. Methodological challenges relate particularly to heterogeneity of the population and to outcome assessment. Heterogeneity pertains both to the range of pathologies included in TBI, and to prognostic factors, each causing specific problems. Mechanistic and/or prognostic targeting, as well as possibilities for covariate adjustment, are suggested as possible solutions to deal with the problems of heterogeneity. The aim in most trials was to demonstrate a 10% absolute improvement in favorable outcome in patients with head injury. This may be considered overoptimistic and unrealistic in relation to the heterogeneous patient population. Specific problems are further incurred by the use of the dichotomized Glasgow Outcome Scale as primary outcome measure. Optimal statistical power may expected to be present when the point of dichotomization results in a 50:50 distribution of outcome categories. It is proposed to differentiate the point of dichotomization according to prognostic risk profile, in order to maintain statistical power. Solutions described may be expected to enhance chances of demonstrating benefit of potentially effective neuroprotective agents in future studies. The complexity of problems occurring in clinical trial design and analysis in TBI is such that a strong and sustained multidisciplinary input and effort is required from all experts involved in the field of neurotrauma.
Insights
Neuroprotective agents for traumatic brain injury (TBI) show limited success due to trial design flaws and patient heterogeneity. Future studies need improved methods to identify effective treatments for specific patient subgroups.
Area of Science:
- Neuroscience
- Clinical Trials
- Pharmacology
Background:
- Numerous neuroprotective agents developed for traumatic brain injury (TBI) have failed to demonstrate efficacy in large phase III trials.
- This lack of success is often misconstrued as agent ineffectiveness, rather than potential issues with trial design and patient population heterogeneity.
Purpose of the Study:
- To address the challenges in clinical trial design and analysis for neuroprotective agents in TBI.
- To propose solutions for enhancing the ability to demonstrate treatment efficacy in future TBI studies.
Main Methods:
- Analysis of methodological challenges in TBI clinical trials, focusing on population heterogeneity and outcome assessment.
- Exploration of strategies such as mechanistic/prognostic targeting and covariate adjustment to manage heterogeneity.
- Evaluation of the Glasgow Outcome Scale's limitations and proposal for risk-profile-differentiated dichotomization to maintain statistical power.
Main Results:
- Negative trial results in the overall TBI population may stem from heterogeneity in pathologies and prognoses.
- The common trial aim of a 10% absolute improvement in favorable outcome may be unrealistic for heterogeneous TBI populations.
- The dichotomized Glasgow Outcome Scale presents statistical power challenges, particularly when outcome distribution is not 50:50.
Conclusions:
- Addressing TBI patient heterogeneity and refining clinical trial design, including outcome measures, is crucial for demonstrating neuroprotective agent efficacy.
- Implementing proposed solutions like targeted patient selection and adjusted outcome assessment can improve the chances of success for future neuroprotective therapies.
- Successful advancement in TBI neuroprotection requires sustained, multidisciplinary collaboration among experts in the field.
